Published in PLoS One on March 23, 2015
Phytochemical, antioxidant and hepatoprotective effects of Alnus nitida bark in carbon tetrachloride challenged Sprague Dawley rats. BMC Complement Altern Med (2016) 0.79
Fraxinus xanthoxyloides leaves reduced the level of inflammatory mediators during in vitro and in vivo studies. BMC Complement Altern Med (2016) 0.78
Protective effects of Fraxinus xanthoxyloides (Wall.) leaves against CCl4 induced hepatic toxicity in rat. BMC Complement Altern Med (2016) 0.77
Protective effect of propofol preconditioning on ischemia-reperfusion injury in human hepatocyte. J Thorac Dis (2017) 0.75
Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells. Theranostics (2017) 0.75
Natural Compounds as Modulators of Cell Cycle Arrest: Application for Anticancer Chemotherapies. Curr Genomics (2017) 0.75
Isoflurane Preconditioning Induces Neuroprotection by Up-Regulation of TREK1 in a Rat Model of Spinal Cord Ischemic Injury. Biomol Ther (Seoul) (2016) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet (1995) 6.60
Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis (2002) 2.70
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene (2013) 2.64
Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res (1998) 1.92
Why target apoptosis in cancer treatment? Mol Cancer Ther (2003) 1.92
Dietary agents for chemoprevention of prostate cancer. Cancer Lett (2008) 1.72
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs (2009) 1.71
New insights into cyclins, CDKs, and cell cycle control. Semin Cell Dev Biol (2005) 1.70
Cyclins and CDKS in development and cancer: lessons from genetically modified mice. Front Biosci (2006) 1.69
Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol (2005) 1.67
Mediterranean diet and prostate cancer risk and mortality in the Health Professionals Follow-up Study. Eur Urol (2013) 1.59
Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev (2001) 1.53
Total cranberry extract versus its phytochemical constituents: antiproliferative and synergistic effects against human tumor cell lines. J Agric Food Chem (2004) 1.52
Hsp90 as a therapeutic target in prostate cancer. Semin Oncol (2003) 1.42
Dietary antioxidant intake and the risk of cardia cancer and noncardia cancer of the intestinal and diffuse types: a population-based case-control study in Sweden. Int J Cancer (2000) 1.18
Soy isoflavones and prostate cancer: a review of molecular mechanisms. J Steroid Biochem Mol Biol (2013) 1.13
Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway. Clin Transl Oncol (2009) 1.10
Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions. Invest New Drugs (2005) 1.06
Cancer therapeutics: Targeting the apoptotic pathway. Crit Rev Oncol Hematol (2013) 1.06
Dietary bioactive compounds and their health implications. J Food Sci (2013) 1.01
Caffeic Acid, a versatile pharmacophore: an overview. Mini Rev Med Chem (2011) 1.00
Quercetin: a pleiotropic kinase inhibitor against cancer. Cancer Treat Res (2014) 1.00
Androgen receptors and their biology. Vitam Horm (2001) 0.98
Low prostate concentration of lycopene is associated with development of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. Int J Mol Sci (2014) 0.96
Fruit consumption reduces the effect of smoking on bladder cancer risk. The Belgian case control study on bladder cancer. Int J Cancer (2006) 0.92
Bioavailability of quercetin: problems and promises. Curr Med Chem (2013) 0.91
Assessment of phytochemicals, antioxidant, anti-lipid peroxidation and anti-hemolytic activity of extract and various fractions of Maytenus royleanus leaves. BMC Complement Altern Med (2013) 0.89
Protective effects of Asian dietary items on cancers - soy and ginseng. Asian Pac J Cancer Prev (2009) 0.89
Preventive and prophylactic mechanisms of action of pomegranate bioactive constituents. Evid Based Complement Alternat Med (2013) 0.88
Death receptors and mitochondria: two prime triggers of neural apoptosis and differentiation. Biochim Biophys Acta (2012) 0.87
Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function. Anticancer Agents Med Chem (2009) 0.87
Prostate cancer: current treatment and prevention strategies. Iran Red Crescent Med J (2013) 0.87
Correlation of cervical cancer mortality with reproductive and dietary factors, and serum markers in China. Int J Epidemiol (1994) 0.86
The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Urol (2014) 0.83
Reflections on cell competition. Semin Cell Dev Biol (2014) 0.81
Dihydroagarofuran sesquiterpene alkaloids from Maytenus putterlickoides. J Nat Prod (2001) 0.80
Pomegranate extracts and cancer prevention: molecular and cellular activities. Anticancer Agents Med Chem (2013) 0.79
Variable expressivity and mutation databases: The androgen receptor gene mutations database. Hum Mutat (2001) 0.78
Sesquiterpenes from Maytenus jelskii as potential cancer chemopreventive agents. J Nat Prod (2010) 0.78
Androgen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells. Cancer Cell Int (2014) 0.76